Novel role for mast cells in omental tissue remodeling and cell recruitment in experimental peritoneal dialysis.
Because of its dynamic structure, the omentum plays a key role in the immunity of the peritoneal cavity by orchestrating peritoneal cell recruitment. Because mast cells accumulate in the omentum upon experimental peritoneal dialysis (PD) and may produce angiogenic/profibrotic factors, it was hypothesized that mast cells mediate omental tissue remodeling during PD. Daily treatment with conventional PD fluid (PDF) for 5 wk resulted in a strong omental remodeling response, characterized by an approximately 10-fold increase in mast cell density (P < 0.01), an approximately 20-fold increase in vessel density (P < 0.02), an approximately 20-fold increase in the number of milky spots (P < 0.01), and a four-fold increase in submesothelial matrix thickness (P < 0.0003) in wild-type rats. In contrast, all PDF-induced omental changes were significantly reduced in mast cell-deficient Ws/Ws rats or in wild-type rats that were treated orally with a mast cell stabilizer cromoglycate. A time-course experiment showed mast cell accumulation immediately before the formation of blood vessels and milky spots. Functionally, PDF evoked a peritoneal cell influx, which was significantly reduced in Ws/Ws rats (P < 0.04) and in wild-type rats that were treated with cromoglycate (P < 0.03). Cromoglycate treatment also completely prevented PDF-induced omental adhesions to the catheter tip (P = 0.0002). Mesothelial damage, angiogenesis, and fibrosis of mesentery and parietal peritoneum as well as glucose absorption rate and ultrafiltration capacity proved to be mast cell independent. Data strongly support the hypothesis that mast cells mediate PDF-induced omental tissue remodeling and, subsequently, peritoneal cell influx and adhesion formation, providing therapeutic possibilities of modulating omental function.
Zareie
Mohammad
M
Department of Molecular Cell Biology and Immunology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands.
Fabbrini
Paolo
P
Hekking
Liesbeth H P
LH
Keuning
Eelco D
ED
Ter Wee
Piet M
PM
Beelen
Robert H J
RH
van den Born
Jacob
J
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D001639:Bicarbonates / Q000494:pharmacology; D004205:Cromolyn Sodium / Q000494:pharmacology*; D015314:Dialysis Solutions / Q000494:pharmacology; D004195:Disease Models, Animal; D007773:Lactates / Q000494:pharmacology; D008297:Male; D008407:Mast Cells / Q000187:drug effects / Q000502:physiology*; D008833:Microcirculation / Q000502:physiology; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D009852:Omentum / Q000166:cytology / Q000503:physiopathology*; D010530:Peritoneal Dialysis; D051381:Rats; D011919:Rats, Inbred Strains; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D001639:Bicarbonates; D015314:Dialysis Solutions; D007773:Lactates; D042461:Vascular Endothelial Growth Factor A; D004205:Cromolyn Sodium